Davita Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Davita Inc trades at $230.93 (market cap $14.92B), while T-Rex 2X Long MSTR Daily Target ETF trades at $2.03. The key difference: Davita Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| DVA | MSTU | |
|---|---|---|
Market Cap | $14.92B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $235.71 | $106.80 |
52-Week Low | $103.87 | $1.46 |
Enterprise Value | $27.47B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
MSTU (T-REX 2X Long MSTR Daily Target ETF) trades at $1.78, down 5.07% today amid significant bearish technical signals. The leveraged ETF tracking MicroStrategy has experienced extreme volatility, with news reports indicating a 95% decline over the past year. Technical indicators show overwhelming bearish momentum with moving averages unanimously negative, while fundamental data remains unavailable for this specialized leveraged product.
The outlook remains highly speculative given the ETF's leveraged structure and dependence on MicroStrategy's Bitcoin-heavy strategy. Investment opportunity exists only for sophisticated traders comfortable with extreme volatility, while risks include daily rebalancing decay, concentration in a single stock, and amplified losses during market downturns.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →